UK Clinical Nutrition for Chronic Kidney Diseases Market Analysis

UK Clinical Nutrition for Chronic Kidney Diseases Market Executive Summary

UK Clinical Nutrition for Chronic Kidney Diseases Market was valued at $40.80 Mn in 2023 and is predicted to grow at a CAGR of 4.03% from 2023 to 2030, to $53.80 Mn by 2030. 

Chronic kidney disease (CKD) is a gradual loss of kidney function over at least three months, often progressing silently due to the absence of early symptoms. The main causes include diabetes and high blood pressure, though family history and other conditions also contribute. As CKD advances through stages, it may necessitate dialysis or a kidney transplant and is associated with increased risks of heart disease, stroke, and bone issues. Management focuses on slowing disease progression, symptom management, and preventing complications through dietary changes, medications, and blood pressure control. Key dietary adjustments include moderating protein intake, managing fluid levels, controlling electrolytes like sodium, potassium, and phosphorus, and ensuring sufficient calorie intake to avoid malnutrition. Early detection and screening are crucial for those at risk.

 CKD in the UK is a significant health concern, especially as it is often asymptomatic and characterized by reduced renal function. In England, approximately 15% of individuals aged 35 and older have CKD, with prevalence rising with age. CKD is independently linked to higher risks of cardiovascular disease and all-cause mortality, with stages ≥3 being major risk factors for progressing to end-stage renal disease (ESRD) and strong predictors of hospitalization. Globally, CKD mortality has surged by one-third over the past decade, contributing to 1.2 Mn deaths annually.

The market therefore is driven by significant factors like the rising prevalence of CKD, technological advancements, and the growing geriatric population. However, the high cost of nutritional products, scarcity of qualified dietitians, and patient adherence restrict the growth and potential of the market.

Prominent players in this field are Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.

Market Dynamics

Market Growth Drivers

Rising Prevalence of CKD: The increasing incidence of chronic kidney disease in the UK, driven by factors such as the aging population, diabetes, and hypertension, creates a growing demand for specialized nutritional products tailored to CKD patients.

Technological Advancements: Ongoing research and development in medical nutrition are leading to the creation of advanced and effective CKD-specific nutritional products. Innovations in formulation and delivery methods enhance patient adherence and outcomes.

Growing Geriatric Population: With a growing geriatric population in the UK vulnerable to CKD, there's a rising demand for tailored clinical nutrition solutions. Currently, over 10 Mn people aged 65 and over comprise 18% of the UK population, emphasizing the need for targeted healthcare approaches.

Market Restraints

High Cost of Nutritional Products: Specialized CKD nutritional products can be expensive, posing a financial burden for patients and healthcare systems. This can limit widespread adoption, especially among lower-income groups.

Scarcity of Qualified Dietitians: The UK is experiencing a shortage of dietitians specializing in CKD nutrition. This shortage restricts patient access to essential expert nutritional guidance, which is crucial for managing various health conditions effectively, including CKD.

Patient Adherence: Ensuring consistent patient adherence to prescribed nutritional regimens can be challenging. Factors such as taste preferences, established dietary habits, and the perceived complexity of nutritional plans can negatively impact adherence rates, leading to reduced demand for clinical nutrition products in the chronic kidney disease market.

Regulatory Landscape and Reimbursement Scenario

The UK market for CKD-specific clinical nutrition is regulated by key bodies including the Food Standards Agency (FSA) and the Medicines and Healthcare Products Regulatory Agency (MHRA). The FSA ensures the safety, quality, and appropriate labeling of food products for special dietary needs, including those for CKD management. The MHRA oversees medical devices and certain nutraceuticals with therapeutic claims, including 'foods for special medical purposes' (FSMPs) specifically formulated for CKD. Key regulations include the General Food Regulations, which mandate clear labeling of intended use, nutrient content, and warnings for CKD products, and adherence to EU regulations that standardize the safety, quality, and labeling of FSMPs across Europe.

The UK's National Health Service (NHS) provides some reimbursement for CKD nutritional interventions. Patients with CKD may receive consultations with qualified dietitians through the NHS, with coverage varying based on individual circumstances and the severity of the condition. Additionally, the NHS may partially reimburse the cost of specific FSMPs deemed clinically necessary for CKD management, with reimbursement criteria set by local commissioning groups. This system ensures that patients have access to necessary dietary support and specialized nutritional products to manage their CKD effectively.

Competitive Landscape

Key Players

Here are some of the major key players in the UK Clinical Nutrition for Chronic Kidney Diseases Market

• Abbott Nutrition
• Pfizer Inc.
• Bayer AG
• Nestlé Health Science
• Otsuka Pharmaceutical
• Mead Johnson & Company, LLC
• Danone S.A.
• Victus, Inc.
• B. Braun Melsungen AG
• Fresenius Kabi AG